Research Findings from University of Jordan Update Understanding of BCR-ABL Tyrosine Kinase Inhibitors (Population Pharmacokinetics of Dasatinib in Healthy Subjects).

Předmět:	PROTEIN-tyrosine kinase inhibitors DASATINIB PHARMACOKINETICS DRUG therapy
Zdroj:	Drug Week; 6/13/2024, p2215-2215, 1p
Abstrakt:	A recent study conducted by researchers at the University of Jordan focused on the population pharmacokinetics of dasatinib, a type of BCR-ABL tyrosine kinase inhibitor used in cancer treatment. The study aimed to investigate the sources of variability in dasatinib levels in healthy participants. The researchers found that body mass index (BMI) had a significant effect on the absorption rate constant of dasatinib, suggesting that BMI could be considered in future dosing regimens for patients. This study provides valuable insights into the pharmacokinetics of dasatinib and its potential implications for personalized medicine. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu